Table 2. Relationship of p53 expression with clinicopathological characteristics.
|
UK patients
|
Dutch patients
|
|||||
|---|---|---|---|---|---|---|
| Normal p53 | Excessive p53 | P-valuea | Normal p53 | Excessive p53 | P-valuea | |
| Age (years) | ||||||
| <58 | 71 (52.2%) | 65 (47.8%) | 0.709 | 50 (56.2%) | 39 (43.8%) | 0.383 |
| ⩾58 | 76 (50.0%) | 76 (50.0%) | 49 (49.5%) | 50 (50.5%) | ||
| FIGO stage | ||||||
| Stage I/II | 30 (50.0%) | 30 (50.0%) | 0.856 | 29 (70.7%) | 12 (29.3%) | 0.006 |
| Stage III/IV | 117 (51.3%) | 111 (48.7%) | 69 (47.3%) | 77 (52.7%) | ||
| Tumour type | ||||||
| Serous | 74 (48.1%) | 80 (51.9%) | 0.273 | 48 (45.7%) | 57 (54.3%) | 0.040 |
| Non-serous | 72 (54.5%) | 68 (45.5%) | 51 (61.4%) | 32 (38.6%) | ||
| Differentiation grade | ||||||
| Grade I | 16 (84.2%) | 3 (15.8%) | 0.003 | 26 (92.9%) | 2 (7.1%) | <0.001 |
| Grade II/III | 112 (48.5%) | 119 (51.5%) | 64 (44.1%) | 81 (55.9%) | ||
| Residual disease | ||||||
| <2 cm | 74 (52.9%) | 66 (47.1%) | 0.404 | 44 (67.7%) | 21 (32.3%) | 0.002 |
| ⩾2 cm | 68 (47.9%) | 74 (52.1%) | 49 (44.5%) | 61 (55.5%) | ||
| Response to chemotherapy | ||||||
| CR/PR | 27 (41.5%) | 58 (58.5%) | 0.139 | 39 (70.9%) | 42 (71.2%) | 0.974 |
| SD/PD | 21 (56.8%) | 16 (43.2%) | 16 (29.1%) | 17 (28.8%) | ||
CR=complete response; FIGO=International Federation of Gynaecology and Obstetrics; PD=progressive disease; PR=partial response; SD=stable disease.
a
P-values were calculated using χ2 or Fisher's exact test, where appropriate.
Bold signifies P<0.05.